加拿大YM BioSciences www.ymbiosciences.com
是为全球病人一家从事癌症药物及急救药品研发及商业化的公司。
2012年Gilead 收购YM BioSciences

   
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

The Company is currently advancing two late-stage products:

Nimotuzumab: an EGFR-targeting Affinity-Optimized Antibody™ in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation, and approved for marketing in over 12 countries.

AeroLEF®: a proprietary, inhaled-delivery composition of fentanyl in development for the treatment of moderate to severe acute pain.